» Articles » PMID: 38449871

Immune Modulatory Roles of Radioimmunotherapy: Biological Principles and Clinical Prospects

Overview
Journal Front Immunol
Date 2024 Mar 7
PMID 38449871
Authors
Affiliations
Soon will be listed here.
Abstract

Radiation therapy (RT) not only can directly kill tumor cells by causing DNA double-strand break, but also exerts anti-tumor effects through modulating local and systemic immune responses. The immunomodulatory effects of RT are generally considered as a double-edged sword. On the one hand, RT effectively enhances the immunogenicity of tumor cells, triggers type I interferon response, induces immunogenic cell death to activate immune cell function, increases the release of proinflammatory factors, and reshapes the tumor immune microenvironment, thereby positively promoting anti-tumor immune responses. On the other hand, RT stimulates tumor cells to express immunosuppressive cytokines, upregulates the function of inhibitory immune cells, leads to lymphocytopenia and depletion of immune effector cells, and thus negatively suppresses immune responses. Nonetheless, it is notable that RT has promising abscopal effects and may achieve potent synergistic effects, especially when combined with immunotherapy in the daily clinical practice. This systematic review will provide a comprehensive profile of the latest research progress with respect to the immunomodulatory effects of RT, as well as the abscopal effect of radioimmunotherapy combinations, from the perspective of biological basis and clinical practice.

Citing Articles

FLASH radiotherapy combined with immunotherapy: From biological mechanisms to blockbuster therapeutics.

Wang Y, Qi S, Bi N, Li Y Transl Oncol. 2024; 51:102183.

PMID: 39613524 PMC: 11629542. DOI: 10.1016/j.tranon.2024.102183.


Deubiquitinating enzyme USP28 inhibitor AZ1 alone and in combination with cisplatin for the treatment of non-small cell lung cancer.

Song Y, Wang L, Zheng Y, Jia L, Li C, Chao K Apoptosis. 2024; 29(9-10):1793-1809.

PMID: 39222275 PMC: 11416398. DOI: 10.1007/s10495-024-02008-6.

References
1.
Wang Y, Huang Y, Ma X, Wusiman D, Zhang X, Bi N . The impact of the COVID-19 pandemic on palliative care practice: A survey of clinical oncologists. Front Public Health. 2022; 10:1020937. PMC: 9719914. DOI: 10.3389/fpubh.2022.1020937. View

2.
Ji X, Jiang W, Wang J, Zhou B, Ding W, Liu S . Application of individualized multimodal radiotherapy combined with immunotherapy in metastatic tumors. Front Immunol. 2023; 13:1106644. PMC: 9877461. DOI: 10.3389/fimmu.2022.1106644. View

3.
Zhai D, An D, Wan C, Yang K . Radiotherapy: Brightness and darkness in the era of immunotherapy. Transl Oncol. 2022; 19:101366. PMC: 8881489. DOI: 10.1016/j.tranon.2022.101366. View

4.
Song X, Si Q, Qi R, Liu W, Li M, Guo M . Indoleamine 2,3-Dioxygenase 1: A Promising Therapeutic Target in Malignant Tumor. Front Immunol. 2022; 12:800630. PMC: 8733291. DOI: 10.3389/fimmu.2021.800630. View

5.
Patel R, Hernandez R, Carlson P, Grudzinski J, Bates A, Jagodinsky J . Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade. Sci Transl Med. 2021; 13(602). PMC: 8449934. DOI: 10.1126/scitranslmed.abb3631. View